Infection Management Test Offered in Key EU Markets

A point of care (POC) test developed by Mologic for detecting infection in patients on peritoneal dialysis (PD), is to be distributed into key European markets including France, Germany, Italy, the Netherlands, Austria and Switzerland by medical technology companies Medisur and Peripal AG.

Widely accepted as a preferred method for managing end-stage renal disease, PD offers greater patient mobility and independence compared to other dialysis options, as well as being gentler to residual kidney function in early-stage disease. Recurring infection, or peritonitis, however, is a major issue for PD patients.

The PERiPLEX® test detects two critical biomarkers of infection in PD waste fluid using a lateral flow immunoassay system and provides a visual result within 10 minutes. A positive result can give PD patients warning of an infection, prompting them to contact their healthcare provider to initiate antibiotic therapy. Earlier identification of infection would enable pre-emptive use of available antibiotics, resulting in improved management of infection and prevention of infection-related damage to the peritoneal membrane.

Mark Davis, co-founder and CEO at Mologic commented: “Establishing a global distribution network is integral to Mologic’s product commercialisation strategy. With the appointment of distributors across Europe we will ensure PERiPLEX is available to more patients, giving them greater choice and the confidence to monitor their dialysis at home. Medisur and Peripal share our mission to improve the lives of patients by bringing diagnostics and treatment closer to home and with highly complementary product portfolios, we look forward to working together.”

The technology was developed following a collaborative project with Cardiff University Medical School, funded by the National Institute of Health Research (NIHR).